Takeda Pharmaceutical

Corza Medical has signed a definitive agreement to acquire Takeda's TachoSil manufacturing operations in Linz, Austria. The acquisition includes the production facility and its experienced manufacturing teams.

GTCR and former NuVasive CEO launched Corza Medical by acquiring Surgical Specialties and merging it with TachoSil, a carve-out from Takeda, creating a surgical technologies company with over $300 million in revenue.

Takeda Pharmaceutical Company received U.S. FDA approval for its new plasma manufacturing facility near Covington, Georgia to produce FLEXBUMIN 25% [Albumin (Human)], USP, 25% Solution. The facility had previously received FDA approval for GAMMAGARD LIQUID in June 2018.

Takeda completed construction of new manufacturing facilities at its Oranienburg site in Germany, costing around €100 million, with subsidies of €23 million. The facility is scheduled to begin operating at end of 2017 and has created about 180 new jobs.

Fujifilm Holdings Corp. announced a tender offer for Takeda Pharmaceutical's 71.2% stake in laboratory chemical maker Wako Pure Chemical Industries Ltd. for 154.7 billion yen ($1.31 billion).